Medical Equipment

Non-Alcoholic Steatohepatitis Biomarkers Market Insights: Revenue Expected to Surpass $3.81 Billion by 2029

December 4, 2025 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the non-alcoholic steatohepatitis biomarkers market from 2025–2034 with trusted insights from The Business Research Company

What Is The Current Size And Expected Growth Outlook For The Non-Alcoholic Steatohepatitis Biomarkers Market?

The non-alcoholic steatohepatitis biomarkers market has experienced substantial growth in its size over recent years. It is anticipated to increase from $1.36 billion in 2024 to $1.68 billion in 2025, achieving a compound annual growth rate (CAGR) of 23.9%. The market’s past expansion is linked to factors including diabetes and metabolic syndrome, the presence of awareness and screening programs, constraints of liver biopsy, regulatory backing, a shift towards personalized medicine, and active clinical trials in NASH.

The non-alcoholic steatohepatitis biomarkers market size is poised for significant growth in the coming years. It is projected to reach $3.81 billion by 2029, demonstrating a robust compound annual growth rate (CAGR) of 22.6%. This anticipated expansion over the forecast period stems from factors such as the emergence of novel therapies, the broadening of precision medicine approaches, patient advocacy initiatives, the integration of multi-omics data, and enhanced patient engagement. Key trends expected during this period include telemedicine and remote monitoring, the development of innovative diagnostic platforms, increased global collaborations in research, technological advancements in biomarker discovery, the integration of artificial intelligence (AI), and the inclusion of imaging biomarkers.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9002&type=smp

Which Growth Drivers Are Propelling The Non-Alcoholic Steatohepatitis Biomarkers Market?

The increasing incidence of liver cancer is anticipated to fuel the expansion of the non-alcoholic steatohepatitis biomarkers market in the future. Liver cancer signifies the development of malignant growths within the liver, which can either originate in the liver itself (primary liver cancer) or spread there from other body parts (secondary or metastatic liver cancer). Non-alcoholic steatohepatitis (NASH) biomarkers are utilized in liver cancer for purposes such as early detection, monitoring disease progression, evaluating treatment response, providing prognostic information, and potentially reducing the need for invasive procedures. For instance, in 2022, the World Cancer Research Fund, a UK-based not-for-profit organization, reported approximately 866,136 new cases of liver cancer globally, making it the 6th most common cancer worldwide. Hence, the rising prevalence of liver cancer is a key driver for the growth of the non-alcoholic steatohepatitis biomarkers market.

Which Segmentation Factors Are Most Significant In The Non-Alcoholic Steatohepatitis Biomarkers Market Analysis?

The non-alcoholic steatohepatitis biomarkersmarket covered in this report is segmented –

1) By Type: Hepatic Fibrosis Biomarkers, Serum Biomarkers, Oxidative Stress Biomarkers, Apoptosis Biomarkers, Other Types

2) By Disease: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity

3) By End Use: Research Institutes And Academics, Diagnostic Centers, Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs), Hospitals And Clinics, Other End-Uses

Subsegments:

1) By Hepatic Fibrosis Biomarkers: Hyaluronic Acid, Procollagen III N-terminal Propeptide (PIIINP), Fibrosis-4 (FIB-4) Index

2) By Serum Biomarkers: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Adiponectin

3) By Oxidative Stress Biomarkers: Malondialdehyde (MDA), 8-Isoprostane, Advanced Oxidation Protein Products (AOPP)

4) By Apoptosis Biomarkers: Caspase-3, Cytochrome c, Liver Inhibitory Protein (LIP)

5) By Other Types: Metabolomic Biomarkers, Genetic Biomarkers, Inflammatory Biomarkers

What New Opportunities Are Emerging From Trends In The Non-Alcoholic Steatohepatitis Biomarkers Market?

Technological advancements are emerging as a significant trend in the non-alcoholic steatohepatitis biomarkers market. Major companies operating in the non-alcoholic steatohepatitis biomarkers market are concentrating on developing innovative solutions to strengthen their market position. For instance, in October 2022, GENFIT, a France-based late-stage biopharmaceutical company, and LabCorp, a US-based life sciences company, concluded a five-year exclusive licensing deal for GENFIT’s NIS4 technology, aimed at assisting in the identification of patients with non-alcoholic-steatohepatitis-at-risk (NASH). NIS4 technology is an innovative, multi-biomarker-based algorithm specifically engineered to identify patients with non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis (F > 2), also known as at-risk NASH. As part of this agreement, LabCorp will develop and commercialize a blood-based molecular diagnostic test utilizing NIS4 technology across the United States and Canada, providing widespread access to healthcare professionals.

Who Are The Most Influential Companies In The Non-Alcoholic Steatohepatitis Biomarkers Market?

Major companies operating in the non-alcoholic steatohepatitis biomarkers market include Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Immuron Ltd, Metacrine

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-biomarkers-global-market-report

Which Region Holds The Largest Share In The Non-Alcoholic Steatohepatitis Biomarkers Market Today?

North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=9002&type=smp

Browse Through More Reports Similar to the Global Non-Alcoholic Steatohepatitis Biomarkers Market 2025, By The Business Research Company

Site Remediation Consulting Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/site-remediation-consulting-services-global-market-report

Psoriasis Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report

Scientific Research And Development Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/scientific-research-and-development-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795